Becton, Dickinson and Company $BDX Shares Sold by Rathbones Group PLC

Key Points

• Rathbones Group PLC trimmed its stake by 21.9% in Q4, selling 10,041 BDX shares and leaving 35,756 shares worth about $6.94 million.
• Becton, Dickinson reported Q results with $2.91 EPS (beat $2.81) but revenue missed at $4.49B versus $5.15B expected, set FY2026 EPS guidance of $12.35–$12.65, and analysts forecast roughly 14.43 EPS for the year.
• The company pays a quarterly dividend of $1.05 (annualized $4.20, yield ~2.7%), its board authorized a $10 million share buyback, and insiders sold 2,713 shares (~$536,881) over the past 90 days.

Rathbones Group PLC trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 21.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 35,756 shares of the medical instruments supplier's stock after selling 10,041 shares during the period. Rathbones Group PLC's holdings in Becton, Dickinson and Company were worth $6,939,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. SOA Wealth Advisors LLC. raised its position in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 95 shares in the last quarter. Activest Wealth Management raised its holdings in shares of Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 97 shares in the last quarter. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. Cornerstone Planning Group LLC increased its position in shares of Becton, Dickinson and Company by 463.3% in the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier's stock worth $30,000 after acquiring an additional 139 shares in the last quarter. Finally, Accredited Wealth Management LLC increased its position in shares of Becton, Dickinson and Company by 77.8% in the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock worth $30,000 after acquiring an additional 70 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Up 0.4%

BDX opened at $155.13 on Tuesday. The firm's 50-day simple moving average is $174.72 and its 200-day simple moving average is $186.24. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The firm has a market cap of $44.17 billion, a price-to-earnings ratio of 25.31, a PEG ratio of 11.20 and a beta of 0.29.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $4.49 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same quarter in the prior year, the firm earned $3.43 EPS. The firm's quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company's dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Citigroup dropped their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating on the stock in a research report on Tuesday, February 10th. Zacks Research downgraded shares of Becton, Dickinson and Company from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 11th. Royal Bank Of Canada set a $172.00 price objective on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Bank of America boosted their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a "neutral" rating in a research note on Monday, January 5th. Finally, Piper Sandler reiterated a "neutral" rating and set a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $191.62.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the company's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 2,713 shares of company stock worth $536,881. Corporate insiders own 0.40% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.